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As a result of the unique functional properties of platelets, more-
robust methods were required for detection of antibodies raised 
against them. Immunofluorescence detection by flow cytometry, 
solid-phase red cell adherence, and antigen capture ELISAs are 
some of the current tests that have been developed to meet the 
challenges of platelet antibody detection and identification and an-
tigen phenotyping. Recently developed protein liquid bead arrays 
are becoming the next-generation platelet antibody tests. Fueled 
by development of PCR and determination of the molecular basis 
of the PlA1 human platelet antigen (HPA), serologic platelet typing 
has now been replaced by genotyping of DNA. Allele-specific PCR, 
melting curve analysis, and 5′-nuclease assays are now evolving 
into more high-throughput molecular tests. Laboratory testing for 
the diagnosis of immune platelet disorders has advanced consid-
erably from its humble beginnings. 
Immunohematology 2009;25:125–135.
Historic Background
Development of suitable tests for detection and iden-tification of platelet antibodies and antigens in the clinical laboratory diagnosis of immune platelet dis-
orders proved difficult compared with the relative ease with 
which simple tests were designed for detection of RBC an-
tibodies and antigens. Homotypic platelet–platelet interac-
tions via cell surface receptors and their ligands caused non-
specific platelet agglutination after centrifugation, thereby 
preventing the application of standard RBC antibody tube 
agglutination tests in the detection of platelet antibodies. In 
addition, isolation and preparation of platelets for testing 
resulted in elevated cell surface immunoglobulin levels that 
significantly reduced assay sensitivity and specificity.1
 Early assays for detection of platelet antibodies used 
the functional properties of platelets as assay end points 
such as protein receptor–induced activation, alpha and 
dense granule release, and platelet aggregation and agglu-
tination. These tests are often referred to as phase I or first-
generation assays and will not be discussed further. Later, 
more sophisticated tests (phase II or second-generation as-
says) included direct or indirect measurements of platelet 
surface-bound immunoglobulins using secondary antibody 
reagents in immunoblots,2 RIA,2–4 ELISA,5–7 immunofluo-
rescence,8–10 latex agglutination,11,12 and solid-phase RBC 
adherence.13,14 With the production of platelet glycoprotein 
(GP)-specific monoclonal antibodies throughout the early 
1980s, phase III or third-generation assays were developed 
that allowed for detection of antibodies bound to platelet 
membrane GPs captured in the wells of microtiter plates.15–18 
More recently, assays using purified platelet GPs covalently 
linked to individual polystyrene beads have been developed 
that greatly increase assay throughput. These same anti-
body detection assays were also used to phenotype platelets 
for the human platelet antigens (HPAs) expressed. How-
ever, serologic typing required the availability of relatively 
large quantities of highly specific typing sera free of HLA 
class I antibodies. With the cloning and identification of the 
HPA-1a (PlA1) gene,19 serologic typing was soon replaced by 
molecular methods for genotyping DNA.19,20
Platelet Glycoproteins and Antigens
 Like RBCs, platelets have their own unique surface 
antigens. To date, 28 different platelet-specific antigens 
carried on five different GPs have been completely char-
acterized. The Platelet Antigen Nomenclature Working 
Party of the International Society of Blood Transfusion 
and International Society of Thrombosis and Hemostasis21 
has assigned 23 HPA-designated systems (Table 1). With 
the exception of one (HPA-14bw), all consist of two alleles 
with the higher frequency allele given the “a” designation 
and the lower frequency allele the “b” designation. A “w” 
(workshop) designation has been assigned to antibodies for 
which the antithetical allelic antigen has not yet been found. 
Platelets also express other “non-HPA” antigens to which 
antibodies are produced that have been implicated in im-
mune platelet disorders including the blood group ABO(H) 
antigens, Nak(a) antigen on GPIV, and HLA class I (Table 
1). A, B, and H antigens are expressed on virtually all major 
platelet membrane GPs, but the majority are expressed on 
GPIIb and platelet endothelial cell adhesion molecule (PE-
CAM or CD31).22 HLA class I A, B, and C antigens are all 
expressed on platelets, which are the major source of HLA 
class I antigen in the blood.23
Immune Platelet Disorders Evaluated by Platelet 
Immunology Laboratories
 Platelet antibody and antigen tests are primarily used 
in the laboratory investigation of six immune platelet dis-
orders: (1) autoimmune thrombocytopenia, often referred 
to as ITP (idiopathic thrombocytopenic purpura), in which 
patients produce antibodies against their own platelets; (2) 
neonatal alloimmune thrombocytopenia (NATP), in which 
maternal IgG antibodies produced against a paternal plate-
let antigen inherited by the child cause destruction of fetal 
and newborn platelets; (3) posttransfusion purpura (PTP), 
an acute, severe thrombocytopenia that develops 5 to 10 
Review
IMMUNOHEMATOLOGY, Volume 25, Number 3, 2009126
days after a blood transfu-
sion in a patient previously 
sensitized to a platelet al-
loantigen during preg-
nancy or prior transfusion 
that leads to autoantibody 
formation; (4) multiplate-
let transfusion refractori-
ness (MPTR), which oc-
curs most frequently in 
oncology patients receiving 
platelet transfusion sup-
port after bone marrow 
transplant or chemothera-
py who become highly al-
loimmunized, primarily to 
HLA class I antigens; (5) 
drug-induced thrombocy-
topenia (DITP), in which 
patients develop acute, 
severe thrombocytopenia 
caused by drug-dependent 
antibodies (DDAbs) that 
develop after exposure to 
various drugs—some of the 
drugs that most commonly 
cause DDAbs are quinine, 
vancomycin, and GPIIb/
IIIa inhibitors; and (6) 
heparin-induced throm-
bocytopenia with throm-
bosis (HITT) or without it 
(HIT)—thrombocytopenia 
develops most often in pa-
tients exposed to unfrac-
tionated heparin, resulting 
in the production of anti-
bodies to platelet-factor 4 
(PF4)—heparin complexes 
that bind to platelet Fc re-
ceptors, leading to platelet 
activation and clearance.
 Detailed descriptions of 
various methods for detec-
tion of platelet antibodies 
and allelic gene polymor-
phisms that encode plate-
let antigens are described 
in this article. The role of 
platelet antibody testing in 
the diagnosis of the various 
immune platelet disorders 
is explored in other articles 
in this issue.
B.R. Curtis and J.G. McFarland






Amino Acid Change Nucleotide Substitution
HPA-1a (PlA1) PlA, Zw 72% a/a GPIIIa / L33P T>C 196
HPA-1b (PlA2) 26% a/b
2% b/b
HPA-2a (Kob) Ko, Sib 85% a/a GPIb  / T145M C>T 524
HPA-2b (Koa) 14% a/b
1% b/b
HPA-3a (Baka) Bak, Lek 37% a/a GPIIb / I843S T>G 2622
HPA-3b (Bakb) 48% a/b
15% b/b
HPA-4a (Pena) Pen, Yuk >99.9% a/a GPIIIa / R143Q G>A 526
HPA-4b (Penb) <0.1% a/b
<0.1% b/b
HPA-5a (Brb) Br, Hc, Zav 80% a/a GPIa / E505K G>A 1648
HPA-5b (Bra) 19% a/b
1% b/b
HPA-6bw Caa, Tu <1% b/b GPIIIa / R489Q A>G 1564
HPA-7bw Mob <1% b/b GPIIIa / P407A G>C 1317
HPA-8bw Sra <0.1% b/b GPIIIa / R636C T>C 2004
HPA-9bw Maxa <1% b/b GPIIb / V837M A>G 2603
HPA-10bw Laa   1% b/b GPIIIa / R62Q A>G 281
HPA-11bw Groa <0.5% b/b GPIIIa / R633H A>G 1996
HPA-12bw Iya 1% b/b GPIb  / G15E A>G 141
HPA13bw Sita  <1% b/b GPIa / M799T T>C 2531
HPA-14bw Oea 1% GPIIIa / De167K AAG 1929-31
HPA-15a (Govb) Gov 35% a/a CD109 / Y703S A>C 2108
HPA-15b (Gova) 42% a/b
23% b/b
HPA-16bw Duva <1% GPIIIa  / T140I C>T 517
HPA-17bw Vaa <1% GPIIIa / T195M C>T 622
HPA- ? Caba <1% GPIa / Q716H G>T 2235
HPA- ? Sta <1% GPIIIa / K137Q A>C 487
HPA- ? Kno <1% GPIIb /  T619M C>T 1949
HPA- ? Nos <1% GPIIIa / E628K G>A 1960
NA Naka 99.8% (Caucasian) CD36 (GPIV)
97% (African) T>G 1264
96% (Asian) C>T 478
NA A, B, H 42% A GPIIb, PECAM, GPIIIa NA
10% B GPIa, GPIIa, GPIV
44% O (H)
4% AB
NA A, B, C NA HLA class I NA
*Phenotypic frequencies for the antigens shown are for the Caucasian population. Significant differences in gene 
frequencies may be found in African and Asian populations. NA = not applicable; ? = HPA number not yet assigned
β
α
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Platelet Antibody Tests Currently Used for the 
Laboratory Investigation of Immune Platelet 
Disorders
Assays using intact platelets
 Despite a good selection of platelet antibody detection 
methods available today, no single method is sufficient.24 
Each method has limitations that make it necessary to 
perform a combination of several methods to ensure a 
thorough antibody workup. Specialized platelet antibody 
reference laboratories typically perform an assay that uses 
intact platelets to screen serum or plasma for antibodies, a 
GP antigen capture assay for identification of the antigen 
that antibodies target, and genotyping of patient DNA to 
help confirm the HPA specificity of platelet alloantibodies 
identified.
Flow cytometry
 The platelet suspension immunofluorescence test 
(PSIFT) using a fluorescence microscope developed by von 
dem Borne et al. in 19788 was the first widely adopted meth-
od using intact platelets for the detection of platelet-reactive 
antibodies. A flow cytometric version of the PSIFT was also 
described in von dem Borne’s original report, and as the in-
struments became more available, immunofluorescence by 
flow cytometry has now become one of the most popular 
and sensitive methods for detection of platelet antibodies 
using intact platelets.9,10,25 A typical assay includes incuba-
tion of patient’s serum or plasma with platelets for 30 to 
60 minutes, usually at room temperature. The platelets are 
then washed to remove unbound and some nonspecifically 
bound immunoglobulins, followed by incubation with fluo-
rescent labeled F(ab′)
2
 fragment of polyclonal anti-human 
IgG for about 20 minutes in the dark. After one wash, the 
platelets are suspended in buffer, and platelet-bound fluo-
rescence is detected by a flow cytometer. Mean or median 
fluorescence intensity (MFI) values and fluorescence his-
tograms are generated by the flow cytometer software for 
use in determining results (Fig. 1). Results can be expressed 
as a fluorescence ratio (FLR) of MFI obtained with the 
patient’s serum divided by MFI obtained with a negative 
control serum from a normal healthy individual incubated 
with the same platelet target. An FLR cutoff for a positive 
interpretation can be established by statistical analysis of 
FLR values obtained from testing 20 to 30 normal sera. Se-
rum or plasma positive control samples should include IgG 
and IgM platelet-reactive antibodies detected in previously 
tested patient samples.
 FITC is the most commonly used fluorescent label for 
the anti-IgG probe. The fluorochrome phycoerythrin (PE) 
attached to an anti-human IgM probe is often used for si-
multaneous detection of IgM platelet antibodies. The two 
labeled probes can be added together during the final incu-
bation, and both activated to fluoresce by the 480-nm 
laser. The fluorescent signals are detected separately 
Fig. 1 Flow cytometry fluorescence dot plot (A1) and histograms 
of platelet antibody test results (A2, and B). (A) Whole blood was 
incubated with a phycoerythrin (PE)-labeled monoclonal antibody 
specific for platelet GPIIb (PE-CD41a), and normal or patient 
serum with HPA-1a antibodies. Platelets were then washed, and 
bound human IgG platelet antibodies were detected by incuba-
tion with FITC-(Fab′)2 fragment of goat anti-human IgG and detection 
of platelet-bound fluorescence by flow cytometry. Platelets were 
identified by gating on PE-CD41a+ fluorescent cells in dot plot 
(A1), and level of FITC-anti-human IgG fluorescence determined 
in histogram (A2) displayed for both normal serum (white) and 
anti-HPPA-1a serum (black). MDFI = median fluorescence in-
tensity. (B) Histograms of drug-dependent platelet antibody test. 
Platelets were incubated with patient serum in the presence (white 
histogram) and absence (gray histogram) of drug, and antibody 
detected with FITC-(Fab′)2 fragment of goat anti-human IgG. Fluo-
rescence is significantly stronger in the presence of drug, indicat-
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because their emission wavelengths differ. F(ab′)
2
 frag-
ments (antibody with Fc end removed) of the anti-immuno-
globulin probes are used to prevent nonspecific binding via 
Fc receptors on the target platelets.
 Flow cytometry has proved to be a very sensitive meth-
od for detection of platelet antibodies and is considered the 
best method for detection of drug-dependent platelet anti-
bodies induced by drugs like quinine,26 sulfamethoxazole,27 
and vancomycin.28 For detection of drug-dependent anti-
bodies the previously described procedure can be used with 
inclusion of a second tube of platelets and serum incubated 
in the presence of the implicated drug at a concentration 
between 1 and 10 mM (Fig. 1).29,30 It is vital that the tube 
of platelets with patient’s serum and drug be washed with 
drug solution to preserve platelet-bound drug-dependent 
antibodies. An FLR is calculated by dividing the MFI ob-
tained with patient’s serum in the presence of drug by the 
MFI obtained with patient’s serum tested with only buffer. 
FLR ratios of 2.0 or greater are usually considered positive 
for drug-dependent antibodies.
 Flow cytometry can also be used for detection of platelet-
associated IgG (PAIgG) and IgM in suspected cases of 
ITP.31–33 The patient’s platelets are simply isolated, washed, 
and incubated with FITC-anti-IgG and PE-anti-IgM; fluo-
rescence is detected by flow cytometry.34 The method is 
sensitive, simple, and relatively quick to perform, but has 
lower specificity owing to nonspecifically bound platelet im-
munoglobulins like immune complexes that can be present 
on platelets of patients with nonimmune thrombocytope-
nias.
 With the adaptation of performing platelet antibody 
flow cytometry tests in 96-well microtiter plates, the use of 
frozen-stored platelets, and the availability of flow cytom-
eters with high-throughput sampler (HTS) attachments, 
flow cytometry has become a quick, high-volume method 
for platelet antibody detection, including as a method for 
platelet crossmatching to select compatible platelets for 
transfusion to highly alloimmunized thrombocytopenic 
patients.35,36 Disadvantages include the requirement for an 
expensive instrument, specialized reagents, and the inabil-
ity to determine antibody HPA specificity in the presence of 
non-HPA antibodies, e.g., HLA class I.
Solid-phase RBC adherence
 Another method for detection of platelet antibodies 
that uses intact platelets is the solid-phase RBC adher-
ence (SPRCA) or mixed-passive hemagglutination assay 
(MPHA), first developed by Shibata et al.13 and later made 
available as a commercial kit (Capture-P, Immucor, Inc., 
Norcross, GA).14,37 SPRCA uses intact target platelets ad-
hered to the wells of a round-bottom 96-well microtiter 
plate. Patient test serum or plasma is added to the wells 
and incubated, followed by repeated washing of the wells. 
Platelet-bound antibodies are detected by addition of in-
dicator RBCs coated with anti-human IgG followed by 
centrifugation at an optimal speed. Results are determined 
by visual examination of the wells. A positive test occurs 
when indicator RBCs bind to antibodies attached to the im-
mobilized platelets, forming a “carpet” of RBCs spread over 
the bottom of the well. In the absence of platelet antibodies, 
centrifugation forces indicator RBCs into a tight button at 
the well bottom.
 SPRCA has been successfully used as a crossmatching 
test, because of its speed and ease of use.14,37 Shortcomings 
include low specificity, subjective end point, short expira-
tion of indicator cell reagent, and inability to determine 
HPA specificity of antibodies in the presence of non-HPA 
antibodies, e.g., HLA class I and ABO. Variations of this 
assay have been developed that use anti-human Ig-coated 
latex beads in place of indicator RBCs, which significantly 
extends the shelf life of the indicator reagent.11
 The importance of including tests that use intact plate-
lets, like flow cytometry and SPRCA, is that the antigenic 
epitopes recognized by platelet-reactive antibodies are bet-
ter preserved on intact platelets. Some HPA-3 antigens can 
only be detected using intact platelets because HPA-3a and 
HPA-3b epitopes are labile in storage or apparently dis-
rupted during detergent solubilization steps required when 
using antigen capture assays,38,39 which are described in the 
next section.
Antigen-capture assays
Antigen-capture ELISA and modified antigen-capture 
ELISA
 The principle of antigen-capture assays is to adhere 
individual platelet GPs, e.g., GPIIb/IIIa, to a solid support 
(polystyrene bead or microtiter plate well) for detection of 
platelet-specific antibodies (Fig. 2). GP captured from pan-
els of platelets with different HPA phenotypes can be used 
to determine the specific HPA (e.g., HPA-1a) recognized by 
antibody present in serum samples.
 The antigen-capture ELISA (ACE)15 and modified 
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Fig. 2 Depiction of three different antigen-capture ELISAs for 
platelet antibody detection and identification: left, antigen-capture 
ELISA (ACE); center, modified ACE (MACE); right, monoclonal 
antibody immobilization of platelet antigens (MAIPA).
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antigen-capture ELISA (MACE)17 are two platelet anti-
gen-capture assays developed in 1987 and 1989, respectively. 
In the ACE, a platelet GP-specific monoclonal antibody is 
adhered by simple electrostatic and hydrophobic interac-
tions to the bottom of a polystyrene microtiter plate well. 
Platelet GPs are released from the cell membrane when 
solubilized in a nonionic detergent such as Triton X-100. 
The platelet lysate is then incubated with the immobilized 
monoclonal antibody to capture the specific GP. The well is 
then washed and incubated with a protein solution, most 
commonly 1 to 2 percent BSA in PBS, to block sites on the 
plastic not coated with antibody-GP complexes to prevent 
nonspecific binding of Ig from patient serum. Serum is 
added to the well and incubated for 30 to 60 minutes at either 
room temperature or 37°C. After multiple washes with buf-
fer, IgG platelet antibodies in the serum that bind to spe-
cific HPA on the GP are detected with an enzyme-labeled 
anti-human IgG reagent after addition of enzyme substrate 
and measurement of the optical density in an ELISA plate 
reader (Fig. 2). In a similar technique, designated the im-
munobead assay, a polystyrene bead instead of a microtiter 
well is used.18 The MACE is simply a modified version of the 
ACE in which platelets are first incubated with serum and 
washed before detergent lysis (Fig. 2). The MACE was de-
veloped to prevent false-positive reactions that can occur in 
the ACE caused by naturally occurring human anti-mouse 
IgG antibodies (HAMA).40,41 HAMA are present at detectable 
levels in about 30 percent or more of human sera. HAMA 
recognize sugar epitopes present on the mouse monoclonal 
IgG antibodies used for GP capture.41 Incubation of patient 
serum with platelets first, followed by washing, removes 
HAMA before addition of GP-antibody complexes to immo-
bilized mouse monoclonal IgG. Dilution of patient serum in 
buffer containing 10 percent mouse serum is often used to 
inhibit interference from HAMA in the ACE.
 The ACE assay not only is used for detection and iden-
tification of platelet alloantibodies, but also has been used 
successfully for detection of platelet autoantibodies in the 
serum of patients with ITP.34 An acid eluate of the patient’s 
washed platelets can be incubated with captured GPIIb/
IIIa, GPIb/IX, and GPIa/IIa, the most common GP targets 
of platelet autoantibodies, as a direct test. Patient’s serum 
can be incubated with the same targets for indirect test-
ing. Elution of autoantibodies from the patient’s platelets 
(breaks up immune complexes nonspecifically attached) 
and testing against platelet GPs significantly increases the 
specificity of the assay.34
Monoclonal antibody immobilization of platelet antigens
 The monoclonal antibody immobilization of platelet 
antigens (MAIPA) assay was developed by Mueller-
Eckhardt and colleagues,16 also in 1987, and is more popu-
lar outside the United States. As in the MACE, platelets are 
first incubated with serum and washed, but then incubated 
with monoclonal antibody and washed again, followed by 
detergent lysis. GP-antibody complexes are captured from 
the lysate by anti-mouse IgG polyclonal antibodies adhered 
to the well of a microtiter plate (Fig. 2). A flow cytometry 
version of the MAIPA has been reported, in which a small 
bead instead of a microplate well was used as a solid sup-
port for monoclonal antibody capture of GP.42
Protein bead arrays
 Antigen capture assays are being developed in which 
individual platelet GPs are attached to polystyrene micro-
beads.43,44 Protein bead arrays of this nature were first de-
veloped and used for detection of antibodies to HLA class 
I and class II antigens.45 These highly sensitive assays are 
now considered standard tests for HLA antibody detection 
and identification. The microbeads used have different bead 
“addresses,” with different antigens attached to beads bear-
ing variable amounts of flourescent dye incorporated into 
them at manufacture. For example, four individual purified 
platelet GPs can be attached to each of four separate beads 
containing different ratios of a green and a red fluorescent 
dye: GPIIb/IIIa on bead 1, GPIb/IX on bead 2, GPIa/IIa on 
bead 3, and GPIV on bead 4 (Fig. 3). The four beads are then 
incubated in the same well of a microtiter plate or test tube, 
together with patient’s serum containing antibodies, for ex-
ample, against GPIIb/IIIa. The beads are then washed and 
incubated with PE-labeled anti-human IgG. Fluorescence 
analysis of beads is performed on a Luminex instrument 
(Luminex Corp., Austin, TX). The Luminex is a small flow 
cytometer with two lasers: one (reporter) laser activates the 
fluorescent-labeled beads to identify their unique fluores-
cent addresses, and the other (detection) laser activates the 
PE-labeled anti-Ig for detection of antibody bound to GP on 
the bead. Each bead emits a specific intensity of light based 
on the amount of green fluorescence it contains (bead ad-
dress), allowing for separation and identification of each of 
the four beads and simultaneous detection of PE fluores-
cence (patient antibody bound). Beads with PE fluorescence 
above an established threshold are interpreted as positive. 
Knowing which GP is attached to a specific, defined bead 
Fig. 3 Depiction of a protein bead array assay for platelet antibody 
detection and identification using microbeads coated with differ-
ent platelet GPs, e.g., GPIIb/IIIa, GPIb/IX, GPIa/IIa, and GPIV. 
Patient’s serum with antibody against GPIIb/IIIa reacts only with 
GPIIb/IIIa beads and is detected with PE-labeled anti-human IgG 
by fluorescence detection as depicted on the right side of the 
figure.
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allows for the determination of GP and HPA specificity (Fig. 
3). Modifications of this method have been reported using 
a standard flow cytometer and GPs attached to PE-labeled 
beads.43 Protein bead arrays are highly sensitive and easily 
adapted to high-throughput applications because multiple 
antibodies with different HPA specificities can be detected 
by multiplexing all GP-coated beads in a single well of the 
plate. Issues with assay specificity have been observed in 
which antibodies are detected in sera from some normal, 
healthy people without previous history of alloimmuniza-
tion. This reactivity is probably related to detection of anti-
bodies in human sera that recognize neoantigens formed by 
conformational changes that occur in GPs when attached to 
the beads (authors’ personal observations).
 Recently, Fujiwara et al.44 applied this technology in the 
form of the immunocomplex capture fluorescence analysis 
(ICFA) assay for detection of platelet and HLA class I anti-
bodies, but instead used GP-specific monoclonal antibodies 
attached to the beads to capture antibody-GP immune com-
plexes from detergent lysates prepared after incubating the 
patient’s serum with platelets. In serum dilution studies, 
the ICFA showed fourfold higher sensitivity compared with 
the SPRCA for detection of anti-HPA5b and anti-GPIV, and 
for detection of HPA-3a antibodies compared with MAIPA, 
but lower sensitivity for detection of HPA-3a when com-
pared with SPRCA.
Tests for heparin-dependent antibodies
 Heparin-induced thrombocytopenia without (HIT) 
or with thrombosis (HITT) is a serious immune-mediated 
complication of heparin therapy characterized by (1) sus-
tained thrombocytopenia that occurs during heparin ther-
apy, (2) a platelet count that recovers after discontinuation 
of heparin, and (3) no other evident cause of thrombocy-
topenia.46 HIT is caused by heparin-dependent antibodies 
(HDA) that target neoepitopes that form on PF4 owing to 
conformational changes induced by association with hepa-
rin. Immune complexes of PF4-heparin-HDA cross-link 
FcγRIIa receptors on platelets, causing platelet activation 
and release of additional PF4 from platelet alpha gran-
ules and formation of more PF4–unfractionated heparin 
(UFH)–HDA complexes. Sensitive laboratory tests can reli-
ably confirm the diagnosis in patients suspected of having 
HIT.47 Two types of tests are available: immunoassays and 
functional assays. Immunoassays detect HDA in patient 
sera that target the PF4 protein complexed with circulat-
ing heparin, whereas functional assays detect activation of 
normal target platelets after exposure to patient antibody in 
the presence of heparin. Several tests have been developed 
for detection of HDA including the PF4 ELISA, platelet ag-
gregation, 14C serotonin-release assay (SRA), and heparin-
induced platelet activation (HIPA) assay. The three most 
frequently used of these assays (PF4 ELISA, SRA, platelet 
aggregation) will be discussed here.
PF4 ELISA
 The PF4 ELISA was developed by Amiral et al.48 af-
ter their discovery that PF4 complexed with heparin was 
the target for most HDA. This finding led to the produc-
tion of several commercial kits for antibody detection. PF4 
complexed with UFH or polyvinyl sulfate (PVS) is bound 
to the wells of a microtiter plate. Patient sera diluted from 
1:50 to 1:100 are added to the wells, and after incubation 
and washing, an enzyme-labeled polyclonal anti-human 
IgG/A/M reagent is added for detection of HDA. Reactions 
with patient sera are typically considered positive if they 
exceed an optical density value of 0.400. Testing the pa-
tient’s serum in parallel with 100 U/mL of added UFH to 
inhibit HDA reactivity can be performed to confirm positive 
results. Although debate still exists about the value of this 
added step,49 it can help distinguish clinically significant 
positives from the many modest positive results seen with 
these highly sensitive assays in patients with a low clinical 
index for HIT.50,51
 Another controversy is over the importance of detect-
ing IgM and IgA antibodies in addition to IgG.52 IgG HDA 
are thought to be more clinically significant because IgM 
and IgA HDA cannot crosslink and activate FcγRIIa recep-
tors on platelets, which is why IgA and IgM HDA are not 
detected in the gold standard SRA. However, reports exist 
of patients with high clinical suspicion for HITT in which 
HDA of only the IgA or IgM class could be detected.53,54 It is 
likely in rare cases that some strong IgM and IgA antibodies 
can cause HIT(T).
Platelet aggregation assay
 The platelet aggregation assay using citrate platelet-
rich plasma (PRP) has been in use for detection of HDA 
since the early 1970s and is commonly used today.47 Platelet 
aggregation is evaluated in a standard platelet aggregom-
eter using PRP incubated 1:1 with patient’s citrate plasma 
and buffer or various concentrations of UFH (0.1–1.0 U/
mL). Results are compared with those obtained with citrate 
plasma from a normal healthy donor. Performing the test 
in a lumi-aggregometer allowing for simultaneous monitor-
ing of platelet activation and release of ATP may increase 
sensitivity of the method. Platelet aggregation is inexpen-
sive and instrumentation is readily available; however, the 
test is time-consuming and lacks sensitivity and specificity 
compared with other assays.
SRA
 The serotonin-release assay (SRA), first described by 
Sheridan et al.55 in 1986, continues to be considered the 
gold standard assay for HDA. The SRA uses washed plate-
lets. They are thought to increase sensitivity, because cal-
cium can be added to optimize platelet activation, and to 
increase specificity, by removing plasma proteins that 
could cause unwanted platelet activation. 14C-serotonin 
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is incubated with citrate PRP, which is taken up by dense 
granules inside the platelets. Platelets are washed once to 
remove plasma and residual radioactivity and suspended 
in Tyrode’s buffer containing physiologic calcium. Labeled 
platelets, heat-inactivated test serum or citrate plasma, and 
0.1 U/mL or 100 U/mL of UFH are incubated in wells of a 
microtiter plate with constant stirring. Sera with HDA acti-
vate platelets to release 14C-serotonin. Platelets are pelleted, 
and released radioactivity is measured in the supernatant 
using a beta counter. Typically sera that release more than 
20 percent of the radioactivity with 0.1 U/mL UFH and less 
than 20 percent at 100 U/mL UFH are considered positive 
for HDA. Testing performed in the presence of blocking 
monoclonal antibodies specific for FcγRIIa can also be per-
formed to demonstrate inhibition of the reaction,47 but this 
step does not confirm that the reaction is heparin-dependent, 
and could actually mask the presence of a non–heparin-
dependent antibody, e.g., HLA class I, HPA, or platelet 
autoantibodies, if testing in the presence of 100 U/mL UFH 
is not also performed. Non-HDA can usually be differentiated 
from HDA because the former will not be inhibited in the 
presence of 100 U/mL UFH.
 Despite being the gold standard, the SRA is a difficult 
assay to master. It also requires the use of relatively fresh 
platelets, good controls, and, of course, radioactivity.
Platelet Antigen Typing
Serologic typing methods
 The platelet antibody detection methods previously 
described have been adapted for use in serologic typing of 
platelet antigens. However, serologic typing has declined 
dramatically in use because it is difficult and time-consuming 
to perform, and requires the availability of large volumes of 
highly specific anti-sera and the need to isolate sufficient 
platelets from whole blood.
Molecular typing methods
 With the development of PCR and determination of the 
molecular basis of HPAs, serologic platelet antigen typing 
was largely replaced by DNA typing. This shift was a highly 
significant event in improving laboratory testing and ad-
vancing the ability to better diagnose alloimmune platelet 
disorders. Typing DNA for allelic variations that determine 
HPA was made possible with identification of the HPA-
1a/1b (PlA1/A2) polymorphism in the gene encoding GPIIIa 
(βIII integrin).19 This finding resulted in development of 
the first genotyping methods for HPA polymorphisms.19,20 
Since then, the explosion in molecular diagnostics during 
the last 15 years has resulted in the development of a variety 
of methods for platelet genotyping that are much improved 
in their speed and accuracy. It is beyond the scope of this 
article to describe every assay; therefore, we will describe 
some of the most common techniques in use today and di-
rect readers to more detailed reviews of the subject.56,57
Allele-specific PCR (ASP)
 Of the 21 biallelic platelet alloantigens described to 
date, 20 are the result of a single nucleotide polymorphism 
(SNP) in the genes that encode the proteins that express 
them (Table 1).21,23 SNPs are single base changes in a gene 
that differentiate one allele from its antithetical allele. For 
example, if the base T is at position 196 of the gene integrin 
beta III (ITGB3) that encodes GPIIIa, then an individual 
expresses the HPA-1a form of GPIIIa; however, if T is re-
placed by a C at position 196 of ITGB3, then the person ex-
presses the HPA-1b form of GPIIIa on his or her platelets. 
Taking advantage of this simple difference, primers com-
plementary to short sequences that flank the 196 position of 
ITGB3 are mixed with patient genomic DNA, individual de-
oxynucleotide triphosphates (dNTPs), Taq polymerase, and 
buffer containing an optimum concentration of Mg2+. The 
mixture is subjected to 20 to 45 cycles of high-temperature 
denaturation of DNA to separate the double strands, fol-
lowed by lowering the temperature to allow the primers to 
attach to (anneal) the separated strands. Thermostable Taq 
polymerase then extends the primers to copy (amplify) the 
stretch of DNA across the area containing the base at posi-
tion 196. The resultant PCR amplicon is then separated out, 
usually on an agarose gel, stained with ethidium bromide, 
and exposed to UV light for visual fluorescence detection of 
the gel band (Fig. 4). If the DNA being genotyped contains a 
C instead of T at 196, then Taq cannot amplify the separated 
DNA strand with the primers complementary to DNA with 
a T at 196, and thus no PCR amplicon forms and no band 
appears in the gel.
Fig. 4 Ultraviolet light transillumination results of ethidium
bromide–stained 2 percent agarose electrophoresis gel showing 
separated allele-specific PCR products from genotyping assay for 
HPA-1. Lane 1: DNA size standards; lanes 2, 4, 6: HPA-1a allele 
typings; lanes 3, 5, 7: HPA-1b allele typings. One individual’s 
HPA-1a/1b genotyping is shown for each pair of lanes: lanes 2 
and 3, HPA-1a/1a; lanes 4 and 5, HPA-1a/1b; lanes 6 and 7, 
HPA-1b/1b. Human growth hormone (HGH) PCR control band is 
denoted by arrow.
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 Allele-specific PCR is relatively simple and inexpen-
sive to perform and continues to be a popular method for 
HPA genotyping.58 The only drawbacks of the method are 
requirements for post-PCR processing and subjective 
interpretation, which combined make typing slower and 
increase the potential for human error.
Melting curve analysis
 Melting curve analysis (MCA) is a method to measure 
the dissociation (melting) attributes of double-stranded 
DNA (dsDNA) that occur during heating.59,60 At higher tem-
peratures, the two strands of dsDNA separate, and the heat 
required for the intrabase hydrogen bonds to be broken is 
dependent on their length, GC content, and complemen-
tarity. One popular method of MCA for platelet antigen 
genotyping uses the LightCycler instrument (Roche Diag-
nostics, Indianapolis, IN).59,60 The assay begins with PCR 
amplification of patient DNA using primer pairs that flank 
the SNP of interest. As PCR product is formed, it is detected 
with fluorescent-labeled oligonucleotide probes that anneal 
to sequences adjacent to the SNP. One is a shorter allele-
specific “reporter” probe and the other, a longer “anchor” 
probe. When both probes are bound, light from a diode 
activates the fluorescent labeled (usually fluorescein) an-
chor probe and the fluorescence resonance energy trans-
fer (FRET) from the anchor probe to the reporter probe 
excites it to fluoresce. The fluorescence signal detected by 
the LightCycler is proportional to the amount of amplicon 
present, allowing for real-time monitoring and quantifica-
tion. For MCA, the temperature is raised after PCR, and the 
shorter reporter probes, which bind to the amplicon with 
reduced stability, dissociate (melt) at lower temperatures, 
resulting in loss of fluorescence signal that can be moni-
tored as a melting curve. The thermal melting point (T
m
) of 
the reporter probes is sequence-specific, allowing for differ-
entiation of two alleles, e.g., HPA-1a and HPA-1b. By taking 
the negative first derivative (–dF/dT) of the melting curve, 
melting temperature histograms for individual probes can 
be created for easy visual comparison and discrimination of 
homozygous wild-type and mutant and heterozygous geno-
types.57 The assay lends itself to multiplexing to increase 
throughput, and it is even possible to find new SNPs by rec-
ognizing changes in the architecture of melting curves (Fig. 5).
5′-Nuclease or TaqMan assay
 The 5′-nuclease or TaqMan assay is another popular 
genotyping method that also uses FRET chemistry.61,62 The 
assay requires two sequence-specific probes, one that will 
hybridize with the DNA sequence containing the SNP for 
one allele (e.g., HPA-1a), and the other specific for the al-
ternate allele (e.g., HPA-1b). Probes are labeled at their 5′ 
end with fluorochromes having different fluorescent emis-
sion spectra and a quencher molecule on their 3′ ends that 
prevents fluorochrome fluorescence as long as the probe is 
intact. Sequence-specific primers that flank the HPA SNP 
of interest are used to amplify the DNA by PCR. Probes 
and primers are added together with DNA for PCR, and as 
Taq polymerase amplifies and extends the primers, the 
5′-nuclease activity inherent in Taq degrades the probe hy-
bridized to the SNP-containing DNA sequence. This releas-
es the 5′ fluorochrome, separating it from the quencher and 
allowing it to fluoresce, which generates a detectable, quan-
tifiable signal. The allele-specific probe that is not comple-
mentary does not bind and prevents Taq from acting on the 
probe to release its fluorescence.
 The 5′-nuclease and MCA methods lend themselves to 
moderately high throughput but are limited in their multi-
plexing capabilities by fluorochrome availability for probe 
labeling.
High-throughput platelet genotyping methods
 Conventional PCR-ASP assays with gel end point 
for platelet genotyping have begun to give way to high-
throughput methods. These methods are not only faster 
and higher volume, but they are less tedious to perform 
and they reduce human errors. Several methods using 
different chemistries and detection platforms have been 
reported, including glass slide and microplate arrays,63 a 
liquid bead array,64 and mass spectrometry.65 Obstacles to 
high-throughput genotyping methods are the high costs of 
instrumentation and specialized reagents and the need for 
experienced individuals to implement, operate, and inter-
pret the data. High-throughput genotyping platforms by 
Fig. 5 Melting curve analysis by LightCycler for human platelet 
antigen (HPA) genotyping. Shorter reporter fluorescence probes 
bind with reduced stability to the DNA template containing the 
HPA SNP of interest, and as the temperature of the reaction is 
slowly raised they dissociate or “melt” off with resultant loss of 
fluorescence signal that displays as a melting curve. Each peak 
represents a different allele (e.g., HPA-3a left peaks and HPA-3b 
right peaks), which allows for genotype determination of homozy-
gous wild-type, heterozygous, and homozygous mutant genotypes, 
as denoted by arrows. Potential new SNPs can be detected with 
this method as “hybrid” peaks that fall between the two individual 
allele peaks, as denoted in the figure.
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nature could have important applications, to screening all 
pregnant women for HPA-1a to identify those requiring an-
tenatal treatment to prevent NATP, and for screening large 
numbers of blood donors to find matched platelet donors 
for highly alloimmunized patients.
 Molecular tests for platelet genotyping are not with-
out limitations. Rare cases have been reported of unknown 
SNPs located near the HPA polymorphism being typed 
that prevent proper annealing of ASP PCR primers and 
probes, causing false-negative results.66 Silent HPA alleles 
and mutations that affect GP conformation, which produce 
discrepant genotype vs. phenotype results, have also been 
reported.67,68 However, once identified these problems can 
be overcome, usually by redesign of primer and probe se-
quences.
Summary
 Platelet antibody and antigen testing has advanced 
considerably since its inception with the use of first-
generation assays that used the functional aspects of plate-
lets for antibody and antigen detection. Introduction of the 
PSIFT assay paved the way for development of even more 
sophisticated flow cytometry immunofluorescence assays, 
solid-phase assays, and monoclonal antigen-capture assays. 
Antigen-capture assays such as the ACE, MACE, and MAI-
PA allowed for not only antibody detection but also identi-
fication of the specific HPA targeted by platelet antibodies 
and serologic typing. Identification of the HPA-1a/1b allelic 
polymorphism in the ITB3 gene enabled development of 
ASP-PCR genotyping assays that quickly replaced serologic 
typing and greatly advanced the field of platelet immunol-
ogy and laboratory diagnosis of immune platelet disorders. 
High-throughput platelet genotyping methods and protein 
bead arrays for platelet antibody detection and identifica-
tion will further advance the field in the coming years.
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